Please ensure Javascript is enabled for purposes of website accessibility

Regeneron Lands a $450 Million "Warp Speed" Contract for Its Prospective COVID-19 Treatment

By Rachel Warren – Updated Jul 8, 2020 at 1:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The funding will help the biotechnology company ramp up mass production of REGN-COV2 at less financial risk before clinical trials reveal whether it works.

Regeneron Pharmaceuticals (REGN 4.25%) announced Tuesday that it had received a $450 million Operation Warp Speed contract for the development and production of REGN-COV2, a COVID-19 treatment candidate. Spearheaded by the Department of Health and Human Services, Operation Warp Speed is a collaboration between several federal agencies, including the National Institutes of Health and the Centers for Disease Control and Prevention, with the core purpose of helping the pharmaceutical industry bring safe and effective COVID-19 countermeasures to market faster.

lap worker injecting sample in vial

Image Source: Getty Images.

Regeneron began initial human trials of REGN-COV2 on June 11. On Monday, the company issued a statement that it had commenced a phase 3 trial in partnership with the National Institute of Allergy and Infectious Diseases to evaluate the efficacy of the "dual antibody cocktail" as a preventative measure for uninfected individuals who have had direct contact with someone infected with COVID-19. Regeneron is also running two concurrent Phase 2/3 studies of REGN-COV2 on hospitalized and non-hospitalized coronavirus patients. 

Assuming the investigational treatment passes regulatory muster, the company has stated that the first doses of REGN-COV2 could be available before the summer is out. It's targeting the production of up to 300,000 treatment doses and 1.3 million preventative doses through autumn 2020. The government has said that if REGN-COV2 is approved, it will distribute the doses from those early lots to the public free of charge.

Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.